DE602004006871D1 - Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen - Google Patents
Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffenInfo
- Publication number
- DE602004006871D1 DE602004006871D1 DE602004006871T DE602004006871T DE602004006871D1 DE 602004006871 D1 DE602004006871 D1 DE 602004006871D1 DE 602004006871 T DE602004006871 T DE 602004006871T DE 602004006871 T DE602004006871 T DE 602004006871T DE 602004006871 D1 DE602004006871 D1 DE 602004006871D1
- Authority
- DE
- Germany
- Prior art keywords
- tweak receptor
- compositions
- methods relating
- soluble fragments
- oligomer soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010014401 TWEAK Receptor Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000016946 TWEAK Receptor Human genes 0.000 title 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000006384 oligomerization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49003603P | 2003-07-24 | 2003-07-24 | |
| US490036P | 2003-07-24 | ||
| PCT/US2004/023904 WO2005010045A1 (en) | 2003-07-24 | 2004-07-23 | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004006871D1 true DE602004006871D1 (de) | 2007-07-19 |
| DE602004006871T2 DE602004006871T2 (de) | 2008-02-07 |
Family
ID=34102961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004006871T Active DE602004006871T2 (de) | 2003-07-24 | 2004-07-23 | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7482430B2 (de) |
| EP (1) | EP1648936B1 (de) |
| JP (1) | JP4823060B2 (de) |
| AT (1) | ATE364050T1 (de) |
| AU (1) | AU2004259355B2 (de) |
| CA (1) | CA2531526C (de) |
| DE (1) | DE602004006871T2 (de) |
| ES (1) | ES2287773T3 (de) |
| WO (1) | WO2005010045A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| US7001992B2 (en) * | 1997-05-30 | 2006-02-21 | Human Genome Sciences, Inc. | Antibodies to secreted protein HEMCM42 |
| JP5550799B2 (ja) | 1999-01-15 | 2014-07-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
| US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| CN102793921A (zh) | 2002-04-09 | 2012-11-28 | 比奥根艾迪克Ma公司 | 用于治疗tweak 相关病症的方法 |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| US20090068102A1 (en) * | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
| EP2332408B1 (de) * | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Behandlung neurologischer Störungen |
| ES2333358T3 (es) * | 2005-04-15 | 2010-02-19 | Rappaport Family Institute For Research In The Medical Sciences | Moleculas y metodos de uso de las mismas para el tratamiento de enfermedades asociadas con mcp-1/ccr2. |
| ES2432564T3 (es) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Tratamiento y evaluación de trastornos inflamatorios |
| ES2507069T3 (es) * | 2005-05-27 | 2014-10-14 | Biogen Idec Ma Inc. | Anticuerpos de unión a TWEAK |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| EP2545938A1 (de) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutische Verwendung von Anti-TWEAK-Rezeptorantikörpern |
| US8039437B2 (en) * | 2008-06-30 | 2011-10-18 | The Trustees Of The University Of Pennsylvania | Fn14/TRAIL fusion proteins |
| CN103153332A (zh) | 2010-09-28 | 2013-06-12 | 卡尔医疗有限公司 | 用于治疗血液恶性肿瘤的组合物和方法 |
| CA2915311A1 (en) * | 2013-06-14 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Anti-tweakr antibodies and uses thereof |
| US12005112B2 (en) | 2017-09-07 | 2024-06-11 | University Of Oslo | Vaccine molecules |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
| US5759546A (en) | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
| CA2280231A1 (en) | 1997-02-12 | 1998-08-13 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
| WO1998054206A1 (en) | 1997-05-30 | 1998-12-03 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| WO2000006698A1 (en) | 1998-07-30 | 2000-02-10 | Human Genome Sciences, Inc. | 98 human secreted proteins |
| US7001992B2 (en) | 1997-05-30 | 2006-02-21 | Human Genome Sciences, Inc. | Antibodies to secreted protein HEMCM42 |
| AU7549498A (en) | 1997-06-03 | 1998-12-21 | Protegene Inc. | Human proteins having transmembrane domains and dnas encoding these prot eins |
| EP1967587A1 (de) | 1997-10-10 | 2008-09-10 | Genentech, Inc. | APO-3-Liganden |
| AU4409099A (en) | 1998-05-29 | 1999-12-13 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
| JP5550799B2 (ja) | 1999-01-15 | 2014-07-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
| CA2394015C (en) * | 1999-12-20 | 2013-11-05 | Immunex Corporation | Tweak receptor |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| CA2408228A1 (en) | 2000-05-08 | 2001-11-15 | Biogen, Inc. | Method for promoting neovascularization |
| CA2422095A1 (en) | 2000-09-14 | 2002-03-21 | Biogen, Inc. | Tweak receptor agonists as anti-angiogenic agents |
-
2004
- 2004-07-23 WO PCT/US2004/023904 patent/WO2005010045A1/en active IP Right Grant
- 2004-07-23 AU AU2004259355A patent/AU2004259355B2/en not_active Ceased
- 2004-07-23 ES ES04779112T patent/ES2287773T3/es active Active
- 2004-07-23 DE DE602004006871T patent/DE602004006871T2/de active Active
- 2004-07-23 US US10/898,575 patent/US7482430B2/en not_active Expired - Fee Related
- 2004-07-23 AT AT04779112T patent/ATE364050T1/de not_active IP Right Cessation
- 2004-07-23 JP JP2006521292A patent/JP4823060B2/ja not_active Expired - Fee Related
- 2004-07-23 EP EP04779112A patent/EP1648936B1/de active Active
- 2004-07-23 CA CA2531526A patent/CA2531526C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004259355A1 (en) | 2005-02-03 |
| DE602004006871T2 (de) | 2008-02-07 |
| JP2007527224A (ja) | 2007-09-27 |
| CA2531526C (en) | 2012-08-21 |
| WO2005010045A1 (en) | 2005-02-03 |
| AU2004259355B2 (en) | 2011-02-03 |
| ATE364050T1 (de) | 2007-06-15 |
| EP1648936A1 (de) | 2006-04-26 |
| ES2287773T3 (es) | 2007-12-16 |
| US7482430B2 (en) | 2009-01-27 |
| EP1648936B1 (de) | 2007-06-06 |
| JP4823060B2 (ja) | 2011-11-24 |
| US20050054047A1 (en) | 2005-03-10 |
| CA2531526A1 (en) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004006871D1 (de) | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| DE602004015810D1 (de) | Substituierte isochinolinderivate und anwendungsverfahren | |
| ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
| SE0301372D0 (sv) | Novel compounds | |
| DE602004024900D1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
| DE60229059D1 (de) | Proteomimetische verbindungen und verfahren | |
| UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
| EP2185197A4 (de) | Neue zellfaktorhaltige lösungszusammensetzungen | |
| UA93375C2 (ru) | Ингибиторы протеинкиназ ha ochobe замещенных амидов | |
| MX2020007898A (es) | Moduladores de cinasa de proteina asociada con rho. | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| NO20063196L (no) | Nye fusjonerte pyrrolokarbazoler | |
| MY153719A (en) | Prokineticin 1 receptor antagonists | |
| WO2005030188A3 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
| WO2005042575A3 (en) | Method for down-regulation of vegf | |
| CY1114075T1 (el) | Ενωσεις αλφα κετοαμιδιου ως αναστολεις πρωτεασης κυστεϊνης | |
| EA201291346A1 (ru) | Полиморфы osi-906 | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
| WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use | |
| IL165007A0 (en) | Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| MY137563A (en) | Ophthalmic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |